| 2025-12-15 |
详情>>
内部人交易：
LO FRANCIS共交易4笔
|
| 2025-11-05 |
详情>>
股本变动：
变动后总股本15266.52万股
|
| 2025-11-05 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.3美元,归母净利润-4592万美元,同比去年增长63.50%
|
| 2025-11-05 |
财报披露：
美东时间 2025-11-05 盘后发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-0.37美元,归母净利润-5546.6万美元,同比去年增长40.82%
|
| 2025-05-01 |
详情>>
业绩披露：
2025年一季报每股收益-0.2美元,归母净利润-2985.2万美元,同比去年增长37.16%
|
| 2025-04-29 |
股东大会：
将于2025-06-10召开股东大会
会议内容 ▼▲
- 1.To elect one Class III director nominee to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2028 annual meeting of shareholders. The nominee for election to the board of directors is Chad Robins;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025;
4.To conduct any other business properly brought before the meeting or any adjournments thereof.
|
| 2025-03-03 |
详情>>
业绩披露：
2024年年报每股收益-1.08美元,归母净利润-1.59亿美元,同比去年增长29.19%
|
| 2025-03-03 |
详情>>
业绩披露：
2022年年报每股收益-1.4美元,归母净利润-2亿美元,同比去年增长3.42%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.86美元,归母净利润-1.26亿美元,同比去年增长19.26%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益-0.73美元,归母净利润-1.06亿美元,同比去年增长8.08%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-0.64美元,归母净利润-9372.9万美元,同比去年增长11.16%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.33美元,归母净利润-4750.7万美元,同比去年增长17.66%
|
| 2024-04-26 |
股东大会：
将于2024-06-07召开股东大会
会议内容 ▼▲
- 1.To elect two Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2027 annual meeting of shareholders. The two nominees for election to the board of directors are Peter Neupert and Michelle Griffin;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024;
4.To conduct any other business properly brought before the meeting or any adjournments thereof.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-1.56美元,归母净利润-2.25亿美元,同比去年增长-12.52%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.08美元,归母净利润-1.56亿美元,同比去年增长2.66%
|
| 2023-04-28 |
股东大会：
将于2023-06-09召开股东大会
会议内容 ▼▲
- 1.To elect two Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2026 annual meeting of shareholders. The two nominees for election to the board of directors are Katey Owen, PhD and Robert Hershberg, PhD, MD;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023;
4.To conduct any other business properly brought before the meeting or any adjournments thereof.
|
| 2022-04-22 |
股东大会：
将于2022-06-10召开股东大会
会议内容 ▼▲
- 1.To elect three Class III director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2025 annual meeting of shareholders. The three nominees for election to the board of directors are Kevin Conroy, Michael Pellini, MD and Chad Robins;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022;
4.To conduct any other business properly brought before the meeting or any adjournments thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-23 |
股东大会：
将于2021-06-11召开股东大会
会议内容 ▼▲
- 1.To elect three Class II director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2024 annual meeting of shareholders. The three nominees for election to the board of directors are Michelle Griffin, Peter Neupert and Leslie Trigg;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers as described in the proxy statement;
3.To approve, on a non-binding advisory basis, the frequency of future advisory votes on named executive officers’ compensation;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2021;
5.To conduct any other business properly brought before the meeting or any adjournments thereof.
|
| 2020-04-24 |
股东大会：
将于2020-06-12召开股东大会
会议内容 ▼▲
- 1.To elect three Class I director nominees to serve on the board of directors of Adaptive Biotechnologies Corporation for a three-year term expiring at the 2023 annual meeting of shareholders. The three nominees for election to the board of directors are David Goel, Robert Hershberg, PhD, MD, and Andris Zoltners, PhD;
2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2020;
3.To conduct any other business properly brought before the meeting.
|
| 2020-03-17 |
复牌提示：
2020-03-16 09:57:56 停牌，复牌日期 2020-03-16 10:07:56
|